Analysts Reiterate Buy Rating for AbbVie Despite EPS Guidance Adjustment

Analysts have reaffirmed their 'Buy' rating for AbbVie (ABBV), characterizing the recent reduction in earnings guidance as mere 'noise' rather than a cause for concern. The downward adjustment in earnings per share (EPS) was primarily driven by In-process Research and Development (IPR&D) expenses and milestone payments instead of operational weakness. In fact, the pharmaceutical giant reported solid 10% revenue growth in the fourth quarter, supported by a healthy adjusted operating margin of 38.3%. The company's drug pipeline continues to show significant promise, highlighted by positive clinical trial results for Skyrizi and ABBV-295. Market experts believe the underlying business remains robust, with technical accounting adjustments masking strong core performance. This outlook suggests that AbbVie's long-term growth trajectory remains intact, providing reassurance to investors in the biotech sector.